Table 2.
Baseline characteristics.
| Category | Variable | Total | Group 1 | Group 2 | p value | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Sociodemographics | Sample size | n (%) | 202 (100%) | 134 (66.34%) | 68 (33.66%) | - | ||||
| Sex | Men | Absolut number | 118 | 79 | 39 | 0.946 | ||||
| Women | 84 | 55 | 29 | |||||||
| Ratio | Men: women | 1.4 | 1.44 | 1.34 | ||||||
| Age (years) |
Mean ± SD | 35.27 ± 14.81 | 34.99 ± 15.85 | 35.82 ± 12.60 | 0.6833 | |||||
| Patients under 18 | Absolut number | 16 | 13 | 3 | 0.27175 | |||||
| Body Mass Index (kg/m2) |
Mean ± SD | 24.93 ± 4.22 | 24.75 ± 4.54 | 25.33 ± 3.42 | 0.3388 | |||||
| Abd. Per. (cm) | Men | Mean ± SD | 92.98 ± 11.29 | 93.01 ± 11.40 | 92.91 ± 11.20 | 0.9659 | ||||
| Women | Mean ± SD | 80.41 ± 14.72 | 79.10 ± 15.69 | 83.25 ± 12.17 | 0.2136 | |||||
| Habits | Physical exercise (days per week) | Mean ± SD | 2.36 ± 2.06 | 2.20 ± 1.97 | 2.70 ± 2.21 | 0.141 | ||||
| Toxic habits | Any (present or past) | Absolut number | Yes | 134 | Yes | 91 | Yes | 43 | 0.590 | |
| No | 59 | No | 37 | No | 22 | |||||
| Unknown | 9 | Unknown | 6 | Unknown | 3 | |||||
| Medical History | CVRF | Absolut number | Yes | 46 | Yes | 34 | Yes | 12 | 0.313 | |
| No | 155 | No | 100 | No | 55 | |||||
| Unknown | 1 | Unknown | 0 | Unknown | 1 | |||||
| Non-atopic comorbidities | Absolut number | Yes | 117 | Yes | 76 | Yes | 41 | 0.737 | ||
| No | 85 | No | 58 | No | 27 | |||||
| Unknown | 0 | Unknown | 0 | Unknown | 0 | |||||
| Allergies | Absolut number | Yes | 168 | Yes | 110 | Yes | 58 | 0.707 | ||
| No | 34 | No | 24 | No | 10 | |||||
| Unknown | 0 | Unknown | 0 | Unknown | 0 | |||||
| Atopic comorbidities | Absolut number | Yes | 146 | Yes | 101 | Yes | 45 | 0.225 | ||
| No | 56 | No | 33 | No | 23 | |||||
| Unknown | 0 | Unknown | 0 | Unknown | 0 | |||||
| Family history of atopic dermatitis | Absolut number | Yes | 101 | Yes | 70 | Yes | 31 | 0.457 | ||
| No | 101 | No | 64 | No | 37 | |||||
| Unknown | 0 | Unknown | 0 | Unknown | 0 | |||||
| Family history of atopic comorbidities (asthma, hay fever) | Absolut number | Yes | 84 | Yes | 57 | Yes | 27 | 0.814 | ||
| No | 118 | No | 77 | No | 41 | |||||
| Unknown | 0 | Unknown | 0 | Unknown | 0 | |||||
| Disease history | Age at debut | Mean ± SD | 13.58 ± 16.81 | 12.89 ± 17.60 | 14.96 ± 15.16 | 0.3909 | ||||
| Disease-free period in life | Number (%) | 59 (29.21%) | 44 (32.84%) | 15 (22.06%) | 0.1533 | |||||
| Years of evolution pre- | Mean ± SD | 20.34 ± 11.86 | 20.67 ± 12.43 | 19.69 ± 10.71 | 0.5616 | |||||
| Visits to ED pre- | Number (%) | 151 (74.75%) | 93 (69.40%) | 58 (85.29%) | 0.0223* | |||||
| Admissions pre- | Number (%) | 16 (7.92%) | 14 (10.45%) | 2 (2.94%) | 0.1116 | |||||
| Seasonal changes in disease severity | Number (%) | 138 (68.31%) | 90 (67.16%) | 48 (70.59%) | 0.978 | |||||
| Treatment history | Use of emolient (days per week) | Mean ± SD | 4.90 ± 2.48 | 4.84 ± 2.50 | 5.01 ± 2.46 | 0.636 | ||||
| Prior exposition to classic systemic therapies | Number (any) | Mean ± SD | 1.78 ± 1.06 | 1.62 ± 0.96 | 2.09 ± 1.19 | 0.0058* | ||||
| CsA | Number (%) | 188 (93.07%) | 122 (91.04%) | 66 (97.06%) | 0.19454 | |||||
| MTX | 65 (32.18%) | 38 (28.36%) | 27 (39.71%) | 0.141 | ||||||
| AZA | 25 (12.38%) | 12 (8.96%) | 13 (19.12%) | 0.06481 | ||||||
| MM | 31 (15.35%) | 16 (11.94%) | 15 (22.06%) | 0.09317 | ||||||
| UV | 39 (19.31%) | 39 (19.31%) | 14 (20.59%) | 0.88862 | ||||||
| IgIV | 11 (5.45%) | 4 (2.99%) | 7 (10.29%) | 0.06646 | ||||||
| Prior exposition to AST | Patients | n (%) | 60 (29.70) | 27 (20.15%) | 33 (48.53%) | 0.0001* | ||||
| Number (any) | Mean ± SD | 0.36 ± 0.70 | 0.21 ± 0.49 | 0.66 ± 0.92 | 0.0003* | |||||
| Biologics | Mean ± SD | 0.18 ± 0.43 | 0.08 ± 0.28 | 0.37 ± 0.60 | 0.0003* | |||||
| JAKi | Mean ± SD | 0.18 ± 0.44 | 0.13 ± 0.33 | 0.29 ± 0.57 | 0.0291* | |||||
The table includes a summary of sociodemographic data, body measurements, lifestyle choices, and non-AD-related past medical history from participants, which have been extensively and more individually characterized in reference (53). Disease history and prior treatment exposure, stratified by treatment group, are more deeply analyzed. Mean ± standard deviation (SD) is given for continuous variables, and absolute numbers and/or percentages for categorical variables. Statistically significant comparisons are indicated in bold (*).